Study Design : All participants received semaglutide 2.4 mg for 20-week run-in period Participants who lost 5% body weight were then randomized to: Continue semaglutide (n=535) Switch to placebo (n=268) Follow-up: Additional 48 weeks (68 weeks total) Results : Continued semaglutide group : Lost additional 7.9% body weight (total 17.4% from baseline) Switched to placebo group : Regained 6.9% body weight (net 9.8% loss from baseline) Interpretation : This trial demonstrates that: Most participants regain significant weight when semaglutide is discontinued Continuing medication supports ongoing weight loss beyond initial reduction Long-term medication use is typically necessary for sustained results Understand the Differences Between FDA-Approved and Compounded Medications Tirzepatide Clinical Evidence: SURMOUNT Trial Program SURMOUNT-1: Primary Efficacy Trial Citation : Jastreboff AM, et al
They are involved in skin pigmentation
Watch for signs of over-exfoliation: persistent redness, increased sensitivity, peeling, or that tight, uncomfortable feeling
Bril F, Kalavalapalli S, Lomonaco R, Frye R, Godinez Leiva E, Cusi K
Reducing miR-137 boosts Erastins antitumor effects by encouraging ferroptosis in both laboratory and live models (48)
